Immuron

Immuron products are available to practitioners, students and clients of practitioners via vital.ly.

 

Immuron Products Ltd is a publicly listed Australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome

 

Phone: +613 8892 4800

Address: Level 3, 62 Lygon Street, Carlton South, VIC 3053

Email: info@immuron.com

 

Immuron’s technology platform is capable of developing and producing an orally stable therapeutic as a potential ‘oral targeted therapy’ for various immune-mediated and inflammatory disorders, among them: non-alcoholic steatohepatitis (NASH) diabetes, colitis, inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), liver fibrosis and other chronic disorders in which the immune system plays a key role in pathogenesis.

 

These disorders represent areas of growing and unmet medical need, where oral targeted therapy drugs could offer significant advantages due to the lack of absorption and the high safety profile